Experiment 66871
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Calloselasma rhodostoma (VIPERIDAE) |
| Citation | SHERMAN,DS: ATKINSON,RP: CHIPPENDALE,T: LEVIN,KA: NG,K: FUTRELL,N: HSU,CY: LEVY,DE:. (2000). INTRAVENOUS ANCROD FOR TREATMENT OF ACUTE ISCHEMIC STROKE.. 283(18) |
| Amount utilized | |
| Compound isolated | |
| Disease | STROKE TREATMENT WITH ANCROD TRIAL, A RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL CONDUCTED BETWEEN AUG 1993 AND JAN 1998. PATIENTS WERE RANDOMLY ASSIGNED TO RECEIVE ANCROD (N=248) OR PLACEBO (N=252) AS A CONTINUOUS 72 INTRAVENOUS INFUSION BEGINNING WITHIN 3 HRS OF STROKE ONSET, FOLLOWED BY INFUSIONS LASTING APPROXIMATELY 1 HR AT 96 AND 120 HRS. THE PRIMARY EFFICACY END POINT WAS FUNCTIONAL STATUS, WITH FAVORABLE FUNCTIONAL STATUS DEFINED AS SURVIVAL TO DAY 90 WITH A BARTHEL INDEX OF 95 OR MORE OR AT LEAST THE PRESTROKE VALUE, COMPARED BY TREATMENT GOURP.PRIMARY SAFETY VARIABLES INCLUDED SYMPTOMATIC INTRACRANIAL HEMORRHAGE AND MOTALITY. IN THIS STUDY, ANCROD HAD A FAVORABLE BENEFIT-RISK PROFILE FOR PATIENTS WITH ACUTE ISCHEMIC STROKE. |
| Dose amount | VAR |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |